Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT00610415
First received: January 25, 2008
Last updated: January 28, 2013
Last verified: January 2013

January 25, 2008
January 28, 2013
December 2007
October 2012   (final data collection date for primary outcome measure)
Quantification of the cancer stem cell population by flow cytometry [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00610415 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study

To see if a limited sampling of tumor tissue from human subjects is a feasible way to gather adequate tissue for cancer stem cell quantification.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Tissue samples

Non-Probability Sample

Eligible patients will have a diagnosis of squamous cell carcinoma

  • Head and Neck Cancer
  • Head and Neck Cancers
Procedure: tumor biopsy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
Not Provided
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:1. Patients with malignant tumors seen at the Stanford University Cancer Center. Eligible patients will have a diagnosis of squamous cell carcinoma (HNSCC) and will have been seen in the Stanford Head and Neck Oncology Program. A decision to undergo surgery at Stanford will have been made, prior to recruiting patients for the study, and prior to obtaining the samples during surgery. (Histological confirmation of the diagnosis need not be made prior to obtaining consent.) 2. A definitive resection of a malignant tumor is planned. 3. Surgeon judgment that the definitive procedure will not be compromised by including

  • FNA
  • Core needle biopsy
  • Cup forceps or punch biopsy of<4mm. 4. Informed consent documented prior to procedure
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00610415
ENT0023, 98543, SU-12142007-934, 10514
Not Provided
Stanford University
Stanford University
Not Provided
Principal Investigator: Dr. A. Dimitrios Colevas Stanford University
Stanford University
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP